1. Medtech Insight
  2. >>Archive

MHRA (Medicines and Healthcare products Regulatory Agency) issues POC (point of care) microalbuminuria test devices report:

Point of care devices for the detection and semi-quantitation of microalbuminuria are the subject of the latest POC urine screening device evaluation report to be published by the UK Medicines and Healthcare products Regulatory Agency (MHRA). The report includes technical and user assessments of analytical performance, suitability for point of care and reliability. The devices evaluated are: Bayer Microalbumin read of the Bayer Clinitek Status urine strip reader, Bayer Microalbustix, Roche Diagnostics' [Chemstrip] Micral test and Diagnostic Chemicals' ImmunoDip urinary albumin.

Point of care devices for the detection and semi-quantitation of microalbuminuria are the subject of the latest POC urine screening device evaluation report to be published by the UK Medicines and Healthcare products Regulatory Agency (MHRA). The report includes technical and user assessments of analytical performance, suitability for point of care and reliability. The devices evaluated are: Bayer Microalbumin read of the Bayer Clinitek Status urine strip reader, Bayer Microalbustix, Roche Diagnostics' [Chemstrip] Micral test and Diagnostic Chemicals' ImmunoDip urinary albumin.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Ultrahuman Launches Home Health Monitoring

 
• By Natasha Barrow

Ultrahuman seeks to “create an environment that aligns with our bodies" by linking environmental parameters collected by Ultrahuman Home to health physiology, measured by the Ultrahuman Ring Air.

FDA Outlines Responsibilities For Owners Of Transferred 510(k)s

 
• By Elizabeth Orr

The US FDA's new draft guidance details the responsibilities of new owners of 510(k) clearances, including making timely updates device listings in FURLS and GUDID to maintain accurate information for safety alerts and recalls. Comments on the draft are accepted until 4 August.

US House Budget Sets FDA FY26 Funding At $3.2B

 
• By Sue Sutter and Derrick Gingery

A US House bill would give the FDA $33.1m more in budget authority than requested by the Trump Administration for fiscal year 2026. The measure was sent to the full House Appropriations committee on a party-line vote.